Evidence map›Paper›PMID 42247051›Full record

ArticleOphthalmology and therapy2026

Understanding Patient Preferences and Their Impact on Adherence to Glaucoma Therapy: A Multicenter Cross-Sectional Study.

Tomás Hernández, Sara Labay, Susana Duch, Carlos Arciniegas, Elena Avila, Cristina Vendrell, Shirin Djavanmardi, Nuris Nuria Gabarró, Naiara Relaño, Alegria Amram and 1 more

Abstract read
In one paragraph

Article in Ophthalmology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Tomás HernándezHospital Clínic de Barcelona, Barcelona, Spain.
Sara LabayHospital Clínic de Barcelona, Barcelona, Spain.
Susana DuchInnova Ocular Verte, Barcelona, Spain.
Carlos ArciniegasInnova Ocular Verte, Barcelona, Spain.
Elena AvilaInnova Ocular Verte, Barcelona, Spain.
Cristina VendrellInnova Ocular Verte, Barcelona, Spain.
Shirin DjavanmardiInnova Ocular Verte, Barcelona, Spain.
Nuris Nuria GabarróInnova Ocular Verte, Barcelona, Spain.
Naiara RelañoInnova Ocular Verte, Barcelona, Spain.
Alegria AmramHorus Pharma Ibérica, Barcelona, Spain.
Elena MilláHospital Clínic de Barcelona, Barcelona, Spain. millagrinoelena@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionGlaucoma is a progressive, irreversible optic neuropathy that leads to the loss of retinal ganglion cells, vision loss, and blindness. Elevated intraocular pressure (IOP) is the only modifiable risk factor, and topical hypotensive eye drops remain the mainstay of treatment, reducing disease progression by up to 60%. However, patient adherence to therapy remains a significant challenge since this disease is usually asymptomatic in its early stages. Patient preferences and individual characteristics play a key role in adherence. This study aimed to obtain further knowledge about patient preferences regarding glaucoma treatment to better understand factors influencing adherence.

methodsA cross-sectional, multicenter survey was conducted in Spain between March and December 2024 among patients with glaucoma receiving topical treatment for more than 6 months. A questionnaire was designed to collect patients' information about their beliefs, preferences, and adherence-related factors.

resultsOf 200 participants, 169 valid responses were analyzed. Most patients were aged 51-74 years, 60.2% were women, and 71.2% had been on treatment for more than 12 months. Although 93.5% recognized the importance of preservatives, only 36.0% reported having received information about them from their ophthalmologist. Preferences between multidose bottles (MDBs, 42.2%) and single-dose units (SDUs, 37.0%) were similar, although younger women (18-30 years) showed a preference for SDUs (p < 0.05). Perceived ease of handling was strongly influenced by prior experience. Most patients considered SDUs as more hygienic, whereas MDBs were perceived as more environmentally friendly; nearly 79% valued ecological impact. Self-reported adherence to therapy was moderate, with 57.6% of participants denying missed doses. Nonadherent patients were more likely to favor reminder systems (74.5%, p = 0.029). Treatment efficacy was ranked as the most important factor, followed by side effects, ease of use, cost, and environmental impact.

conclusionsThis study highlights substantial variability in patient preferences and underscores the importance of personalized, patient-centered glaucoma care. Enhanced education on preservatives, improved communication, and sustainable packaging could improve adherence and satisfaction. Larger multicenter studies are needed to confirm these findings and inform long-term adherence strategies.

Indexed as

AdherenceGlaucomaHypotensive eye dropsPackagingPatient preferences

Identifiers

PMID42247051
PMCPMC13315633

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.